WW InternationalWW
Recorded

WW International 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration37 minParticipants9

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good day, and welcome to the WeightWatchers Third Quarter 2026 Earnings Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note, this event is being recorded. I would now like to turn the conference over to Ryan Wheeler, Director of Investor Relations.

Ryan WheelerDirector of Investor Relations

Please go ahead. Thank you for joining us today for WeightWatchers Third Quarter 2026 Earnings Conference Call.

Ryan WheelerDirector of Investor Relations

Earlier this morning, we released the shareholder letter and press release for our third quarter 2026 results, which are available on the company's corporate website located at corporate.ww.com. The purpose of this call is to provide investors with some further details regarding the company's financial results, as well as to provide a general update on the company's progress. Reconciliations of non-GAAP measures disclosed on this conference call to the most directly comparable GAAP financial measures are available as part of the shareholder letter and press release. Before we begin, let me remind everyone that this call will contain forward-looking statements. Investors should be aware that any forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from those discussed here today.

Ryan WheelerDirector of Investor Relations

These risk factors are explained in detail in the company's latest annual report on Form 10-K, quarterly reports on Form 10-Q, the earnings press release, the shareholder letter, and as updated by the company's other filings with the Securities and Exchange Commission. Please refer to these filings for a more detailed discussion of forward-looking statements and the risks and uncertainties of such statements. All forward-looking statements are made as of today, and except as required by law, the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Joining today's call are Stephen Bye, President and Chief Executive Officer, Felicia DellaFortuna, Chief Financial Officer, and Jon Volkmann, Chief Operations Officer. Stephen, I'll turn the call over to you.

Stephen ByePresident and CEO

Thank you, Ryan. Good morning, everyone. Since this is my first earnings call as CEO, I want to share with you why I decided to join the WeightWatchers team. It's very simple. I came here because I believe this company can win in a large and growing market. I spent most of my career in subscription and service businesses, and I know how important it is to earn and maintain members' trust, delivering value day after day and month after month. This is an incredible brand with a remarkable history, and few companies have had such a positive and meaningful impact on so many people's lives. Since joining WeightWatchers, I've made it my priority to spend time listening to our members, attending workshops, talking to our coaches, our registered dieticians, our clinicians, and my colleagues.

Stephen ByePresident and CEO

What has stood out for me is that we have an incredible team that cares deeply about our members and what we do every day. The weight loss journey is very personal, and the support people need changes significantly along the way. The weight loss industry is also evolving at an unprecedented pace. Today, access to GLP-1 medication is becoming increasingly commoditized, and new options are coming. With expanding market access, these medications are becoming more affordable and widely available to more people, including seniors through the Medicare GLP-1 Bridge Program. As the barrier to entry for GLP-1 prescriptions continues to decrease, a critical gap is emerging in the market, the acute need for ongoing guidance, including nutritional and behavioral support. We see the total addressable market growing, in part driven by the accessibility of GLP-1 medications. Whether you're on or off medication, people still need the support we provide.

Stephen ByePresident and CEO

They still need to develop foundational habits that sustain healthy weight loss over a lifetime. That is why WeightWatchers has three unique offerings, Core+, and Med+, designed to support members wherever they are in their journey. The results prove the value of our holistic approach. WeightWatchers Med+ members who are prescribed GLP-1 medication and also regularly engaged in our GLP-1 Success Program lost 29% more body weight on average at 12 months than those who did not engage with our structured behavioral support program. The benefits are long-term too. Med+ members who engage with our behavioral support were able to achieve more than 20% weight loss on average after three years. Our science-backed behavioral support and human connection truly sets us apart. Our integrated platform is built to support members wherever they are on their journey, regardless of where they obtain their medication.

Stephen ByePresident and CEO

Whether a member accesses clinicians trained to support people with obesity through our Med+ offering or receive a prescription from their own healthcare provider or through an online pharmacy, our GLP-1 Success Program provides the essential behavioral and community support they need. As anyone who's been on a weight loss journey can tell you, losing weight is not a straight line. Our members' needs change over time. No matter where they are on their path, we provide the support they need through our platform, our digital tools, and with both in-person and virtual workshops. We'll continue to bring together the best of science-backed behavioral support, clinical care, and human connection to support our members. The third quarter's results are evidence of the unique approach we take at WeightWatchers. Our members are responding to our high-value offerings.

Stephen ByePresident and CEO

We increased clinical revenue 48% year-over-year, the largest year-over-year increase of any quarter in 2026. We achieved a fourth straight quarter of sequential Core+ subscriber growth, and overall, we generated positive operating cash flow of $32 million. While we are laser-focused on this strategic evolution, we'll continue to be highly disciplined in our operations. The top-line progress in our high-value tiers, combined with careful expense management and disciplined marketing allocations, generated $51.7 million of Adjusted EBITDA in the third quarter, representing a strong 33.8% margin. Now with that, I'll turn it over to Felicia to discuss the financial results for the third quarter.

Felicia DellaFortunaCFO

Good morning, and thank you, Stephen. Our third-quarter results demonstrate continued progress in our higher-value offerings. Core+ and Med+ now generate roughly half of our revenue. Core+ subscribers grew sequentially for a fourth consecutive quarter, a milestone we have not achieved for 20 years, one we had to blow the dust off old filing cabinets to confirm. This higher-value behavioral tier showed 16% growth in subscribers year-over-year. In addition, clinical subscription revenue has grown more than 30% year-over-year in every quarter this year, including 48% in the third quarter. Alongside this progress, we delivered $51.7 million of Adjusted EBITDA, $15.1 million of positive net income, and $32.3 million of operating cash flow. I am proud of this team's ongoing work and the continued progress made since our financial reorganization in June 2025. Now, turning to subscribers. We ended the quarter with approximately 2.3 million total subscribers.

Felicia DellaFortunaCFO

Behavioral subscribers were approximately 2.1 million, down 26% year-over-year, with the decline concentrated in our Core tier. Within behavioral, our Core+ tier continues to gain share, ending the quarter with 546,000 subscribers and now representing nearly a quarter of our total subscribers, up from 16% a year ago. Importantly, the number of Core+ members enrolled in our GLP-1 Success Program has more than doubled since January, reinforcing the growing relevance of our structured behavioral approach as weight loss medications become more widely used. Clinical ended the quarter with 174,000 subscribers, up 40% year-over-year, and down from 197,000 at the end of June. As we expected in August, the sequential decline largely reflects the one-year mark of our transition off compounded semaglutide, with the 12-month plans introduced during that transition coming up for renewal in Q3 2026.

Felicia DellaFortunaCFO

Alongside that, the recalibration of our marketing spend across the portfolio also contributed. The deliberate recalibration of marketing spend across our portfolio has also supported two growing offerings, Core+ and Med+, with differentiated ways to serve members using GLP-1 medications. Monthly subscription revenue per average subscriber, or ARPU, increased 14% year-over-year to $21, reflecting the continued shift in our subscriber mix toward higher-value offerings. Within behavioral, Core+ generates approximately twice the ARPU of Core, and clinical ARPU was $68, roughly five times the value of Core. Turning to revenue. Third-quarter revenue was $152.9 million, down 11% from $172.1 million a year ago. Behavioral subscription revenue declined 22% to $113.9 million, primarily reflecting the smaller Core subscriber base, partially offset by the growing contribution from Core+. Clinical subscription revenue increased 48% to $38 million and represented approximately 25% of total revenue, compared with 15% a year ago.

Felicia DellaFortunaCFO

We continue to make progress on gross margin. Adjusted gross margin improved to 74.6%, our highest level of 2026. Importantly, this performance comes even as clinical, which has a higher cost of service, grew as a share of total revenue. Continued workflow automation and more efficient delivery of our services have contributed to our strong margin profile. Marketing expense was $33.1 million, or 21.6% of revenue, compared with $48.4 million, or 28.1% of revenue a year ago. Our investment to date in 2026 reflects deliberate timing and allocation across the portfolio. During Q1, our peak season marketing investment was more heavily concentrated in our Med+ offering to support the Wegovy pill launch, as well as included increased brand awareness to educate consumers of our Med+ offering. Q2 and Q3 included a more balanced allocation across our portfolio as we managed offerings with different maturities and margin profiles.

Felicia DellaFortunaCFO

Product development expense was $5.2 million, or 3.4% of revenue, compared with 4.4% a year ago. Adjusted selling, general, and administrative expense was approximately $25 million, or 16.4% of revenue, down from 17.8%, reflecting continued cost discipline. We generated positive net income of $15.1 million, our first two consecutive quarters of positive net income since the emergence. Adjusted EBITDA increased 21% to $51.7 million, and adjusted EBITDA margin improved to 33.8%, compared with 24.9% in Q3 2025. This performance reflects the operating improvements we have made, and this was deliberate timing and allocation of marketing investments. Net income also benefited from lower depreciation and amortization and lower interest expense following our second quarter debt reduction. Turning to liquidity. We ended September with $126.4 million of cash and cash equivalents, up approximately $25 million from the end of June.

Felicia DellaFortunaCFO

We generated $32.3 million of operating cash flow during the quarter after $11.4 million in interest payments on our term loans and invested approximately $7 million in capitalized software and website development. Following our financial reorganization in June 2025, we have reduced total debt by more than 70%, from approximately $1.6 billion to $423.6 million. This stronger financial position supports continued strategic investment in the business while maintaining financial flexibility. Turning to our full-year outlook, we are narrowing our 2026 guidance ranges. We now expect revenue of $625 million-$630 million, compared with our previous range of $620 million-$635 million, and adjusted EBITDA of $110 million-$115 million, compared with our previous range of $105 million-$115 million. We expect clinical subscription revenues to represent approximately 25% of full-year revenue, compared with approximately 16% in 2025.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day